Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Skye Bioscience, Inc. (Nasdaq: SKYE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Skye is a Nevada corporation and clinical-stage biotechnology company focused on metabolic health, and its filings offer structured insight into its financial condition, clinical programs, and material corporate events.
Investors researching SKYE can use this page to review current and historical reports such as Form 8-K, where Skye has furnished press releases on topics including topline CBeyond™ Phase 2a data for nimacimab, financial results for specific reporting periods, and other corporate updates. These 8-K filings link clinical milestones—such as Phase 2a obesity trial readouts, extension study enrollment, and Phase 1b results in metabolic-associated steatotic liver disease—to the company’s formal disclosure record.
Through Stock Titan, Skye’s filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents, allowing users to quickly understand the context of complex clinical and financial information. This includes highlighting how Skye describes nimacimab’s development status, safety and efficacy data reported in furnished press releases, and the company’s stated plans for future clinical studies.
In addition to event-driven Form 8-Ks, users can locate Skye’s annual and quarterly reports, once available, to examine consolidated financial statements, research and development expenditures, and risk factor discussions related to its obesity and metabolic health programs. The filings page also provides a path to monitor any future ownership and insider transaction disclosures, such as Form 4 filings, when they are reported. Together, these documents form a detailed regulatory history that supports deeper analysis of SKYE as a clinical-stage biotech issuer.
Skye Bioscience filed its 2026 proxy statement and CEO letter summarizing 2025 progress and items for shareholder vote. The letter highlights CBeyond™ proof-of-concept results for nimacimab combined with semaglutide (26-week additional weight loss; 22.3% mean weight loss at 52 weeks in the combination cohort) and an encouraging safety profile through 52 weeks. The company says the 200 mg weekly monotherapy dose likely underexposed peripheral tissues and has initiated a higher-dose expansion to generate safety and PK data and inform a planned Phase 2b, while advancing a high-concentration formulation and evaluating Halozyme’s ENHANZE® technology for higher-exposure subcutaneous delivery.
The proxy solicits votes to elect six directors, ratify CBIZ CPAs P.C. as auditor, approve an amendment to increase authorized common shares from 100,000,000 to 300,000,000, and to hold an advisory say-on-pay vote. The CEO letter also describes early proof-of-concept for an antibody-peptide conjugate program and ongoing capital discipline and execution priorities for 2026.
Skye Bioscience, Inc. is soliciting proxies for its 2026 virtual annual meeting to elect six directors, ratify CBIZ CPAs P.C. as auditor and seek stockholder approval to amend the Articles of Incorporation to increase authorized common shares from 100,000,000 to 300,000,000. The proxy and CEO letter highlight clinical progress for nimacimab including a 22.3% mean weight loss at 52 weeks in a combination cohort and a move to higher-dose expansion to inform Phase 2b design.
The company emphasizes preparing a Phase 2b plan, advancing higher-concentration subcutaneous formulation work with Halozyme ENHANZE® technology, and developing an antibody-peptide conjugate program. The board recommends voting "For" all proposals; record date and meeting logistics are provided in the proxy materials.
Skye Bioscience, Inc. filed an amended current report to correct a clerical error in an earlier disclosure about stock options. The company now states that the total number of shares of common stock underlying all repriced options is 2,458,158 shares. No other aspects of the prior report were changed.
Skye Bioscience, Inc. approved a broad stock option repricing and appointed a new chief financial officer. Effective March 31, 2026, all eligible employee stock options granted before December 31, 2025 under the company’s incentive plans had their exercise prices reset to $0.6150 per share, matching the common stock’s closing price that day. This affects 2,420,978 shares in total, including options for the CEO and COO, and is intended to retain and motivate employees without issuing additional equity or cash compensation.
On the same date, the board named John P. Sharp as Chief Financial Officer and principal financial and accounting officer. His services are provided through a Master Services Agreement with Lohman & Associates, under which the company pays $25,600 per month for up to 64 hours of CFO and related advisory services.
Skye Bioscience director Karen L. Smith received a grant of stock options covering 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. They vest in equal monthly installments over the one-year period beginning March 31, 2026. Following this grant, she holds 75,000 stock options directly.
Skye Bioscience Chief Scientific Officer Christopher Twitty reported compensation-related stock option changes with no open-market trading of common shares. On March 31, 2026, he received several new stock option grants, including 200,000 options, 150,000 options, and 75,000 options to buy common stock at exercise prices of $0.615 or $0.610 per share.
The filing also shows matching dispositions back to the company of older options with higher exercise prices ranging from $2.89 to $14.56, effectively repricing these awards. Footnotes explain that the board approved a one-time repricing to $0.615 per share for certain options and clarify multi-year monthly vesting schedules and a prior administrative vesting disclosure error.
Skye Bioscience director Annalisa Jenkins received a new stock option grant covering 75,000 shares of Common Stock. The option has an exercise price of $0.615 per share and expires on March 31, 2036. It vests in equal monthly installments over one year beginning March 31, 2026.
Skye Bioscience Chief Operating Officer Diep Tuan Tu filed an amended insider ownership report to add previously omitted equity awards. The filing lists restricted stock unit awards for up to 72,833 shares that vest in stages when Skye’s market capitalization reaches $125M, $250M, $400M and at an exit of $500M or greater, with acceleration upon a change in control. It also details an additional RSU grant vesting in three equal annual installments from December 14, 2021. Several stock option grants are disclosed, including options over 8,000 shares at an exercise price of $11.25 expiring in 2030, and options over 7,080, 22,021 and 9,194 shares at $3.50–$14.50 per share expiring between 2031 and 2033, all subject to service-based vesting and full vesting on a change in control.
Skye Bioscience director Deborah H. Charych received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $0.6150 per share, expires on March 31, 2036, and was awarded at no cost as a compensation grant.
The stock option vests in equal monthly installments over a one-year period beginning March 31, 2026. Following this grant, Charych holds 75,000 stock options directly, giving her the right to buy an equivalent number of common shares if she chooses to exercise in the future.
Skye Bioscience director Paul A. Grayson received a grant of stock options for 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. The award vests in equal monthly installments over one year beginning March 31, 2026, and represents his full reported option holdings from this filing.